In particular, robust evidence from several studies focus on CSF YKL-40 that shows a fair classificatory capability in differentiating between AD individuals and controls as well as in predicting the progression from the asymptomatic to later prodromal and dementia stages (166–168). This evidence concerns the gene CHI3L1 and Alzheimer disease.